- Home
- NIO vs ICLR Comparison
NIO vs ICLR Comparison
Compare NIO & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NIO | ICLR |
|---|---|---|
| Founded | 2014 | 1990 |
| Country | China | Ireland |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8B | 14.3B |
| IPO Year | 2018 | 1998 |
Fundamental Metrics
Financial Performance| Metric | NIO | ICLR |
|---|---|---|
| Price | $4.78 | $201.67 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 14 |
| Target Price | $6.73 | ★ $202.38 |
| AVG Volume (30 Days) | ★ 39.3M | 759.2K |
| Earning Date | 11-25-2025 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 7.47 |
| Revenue | ★ $10,189,444,895.00 | $8,102,602,000.00 |
| Revenue This Year | $33.27 | N/A |
| Revenue Next Year | $50.24 | $0.66 |
| P/E Ratio | ★ N/A | $26.44 |
| Revenue Growth | ★ 14.90 | N/A |
| 52 Week Low | $3.02 | $125.10 |
| 52 Week High | $8.02 | $228.29 |
Technical Indicators
Market Signals| Indicator | NIO | ICLR |
|---|---|---|
| Relative Strength Index (RSI) | 37.96 | 71.11 |
| Support Level | $4.95 | $180.48 |
| Resistance Level | $5.38 | $184.93 |
| Average True Range (ATR) | 0.19 | 5.59 |
| MACD | 0.04 | 1.52 |
| Stochastic Oscillator | 3.33 | 96.33 |
Price Performance
Historical ComparisonAbout NIO NIO Inc. American depositary shares each representing one ordinary share
Nio is a leading electric vehicle maker, targeting the premium segment. Founded in November 2014, Nio designs, develops, jointly manufactures, and sells premium smart electric vehicles. The company differentiates itself through continuous technological breakthroughs and innovations such as battery swapping and autonomous driving technologies. Nio launched its first model, its ES8 seven-seater electric SUV, in December 2017, and began deliveries in June 2018. Its current model portfolio includes midsize to large sedans and SUVs. It sold around 222,000 EVs in 2024, accounting for about 2% of the China passenger new energy vehicle market.
About ICLR ICON plc
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.